SCHEMBL172237

SCHEMBL172237

CCN(CC)C(C)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.52
HRH1 P35367 2/20 0.52
PGR P06401 1/20 0.52
ADRA2A P08913 1/20 0.52
ADRA2B P18089 1/20 0.52
KCNH2 Q12809 1/20 0.52
FFAR3 O14843 1/20 0.40
FDPS P14324 1/20 0.39
TP53 P04637 1/20 0.38
BCHE P06276 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
ACHE P22303 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
CHRM1 P11229 1/20 0.36
AKR1A1 P14550 1/20 0.36
CHRM3 P20309 1/20 0.36
HTR2C P28335 1/20 0.36
ADRA1A P35348 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304130 1.00 HTR2A (0.52) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL10207211 1.00 HTR2A (0.52) HTR2AHRH1PGRADRA2AADRA2B
Hydrochloric Acid SCHEMBL4356665 0.97 HTR2A (0.50) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL9764180 0.89 HTR2A (0.44) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL3200413 0.85 HTR2A (0.41) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL10064563 0.85 ADRA2A (0.41) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL7904494 0.85 HTR2A (0.41) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL17636225 0.85 ADRA2A (0.41) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL27277859 0.84 HTR2A (0.40) HTR2AHRH1PGRADRA2AADRA2B
SCHEMBL10207192 0.82 PGR (0.39) HTR2AHRH1PGRADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 515 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118125936-A N-acyl ethanolamide derivative, preparation method and application thereof 南京清普生物科技有限公司 2024-06-04 CN claimed
CN-116469621-B Production process of ultrathin transposed conductor 沈阳宏远电磁线股份有限公司 2023-09-12 CN claimed
CN-116469621-A Production process of ultrathin transposed conductor 沈阳宏远电磁线股份有限公司 2023-07-21 CN claimed
EP-3335720-A1 C-DI-GMP BINDING PEPTIDES Universität Basel (CH) 2018-06-20 EP claimed
EP-1098871-B1 alpha-AMINO ACID PHENYL ESTER DERIVATIVES AKZO NOBEL NV (NL) 2003-07-09 EP claimed
EP-0938496-A1 HEPTAPEPTIDE OXYTOCIN ANALOGUES FERRING B.V. (NL) 1999-09-01 EP claimed
WO-1998023636-A1 HEPTAPEPTIDE OXYTOCIN ANALOGUES FERRING B.V. (NL) 1998-06-04 WO claimed
US-4196204-A ANTIANDROGENS, ACNE, SEBORRHEA SCHERING AKTIENGESELLSCHAFT (DE) 1980-04-01 US claimed
US-4112078-A ACYLATION, REDUCTION, ZOAPATLE ORTHO PHARMACEUTICAL CORPORATION (US) 1978-09-05 US claimed
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2026-02-17 US disclosed
US-20260028375-A1 POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES ETH ZUERICH (CH) 2026-01-29 US disclosed
US-12522647-B2 Beta-arrestin mutants PAUL SCHERRER INSTITUT (CH) 2026-01-13 US disclosed
US-12479819-B2 Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-11-25 US disclosed
US-4337311-A 15 Hydroxylation of 1α,2α-methylene steroids SCHERING AKTIENGESELLSCHAFT (DE) 1982-06-29 US disclosed
US-4327039-A Process for the production of 3-amino-1-hydroxypropane-1,1-diphosphonic acid HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 1982-04-27 US disclosed
EP-0027982-A1 Process for preparing 3-amino-1-hydroxypropane-1,1-diphosphonic acid Henkel Kommanditgesellschaft auf Aktien (DE) 1981-05-06 EP disclosed
US-4196204-A ANTIANDROGENS, ACNE, SEBORRHEA SCHERING AKTIENGESELLSCHAFT (DE) 1980-04-01 US disclosed
US-4054598-A SEQUESTERING AGENTS HENKEL & CIE GMBH (DT) 1977-10-18 US disclosed
US-3954845-A Synthetic detergents of the ampholytic betaine type, process for preparing the same and compositions MODOKEMI AKTIEBOLAG (SW) 1976-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028375-A1 POLYPEPTIDES SELF-ASSEMBLING INTO NANOPARTICLES PHAX, TPX2, MLX HTR2A 2841/4885HRH1 1574/4885PGR 4751/4885
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 HTR2A 2669/4885HRH1 1996/4885PGR 3289/4885
US-12552839-B2 Cyclic peptides for protection against respiratory syncytial virus CTH, VIP, CXCL10 HTR2A 4372/4885HRH1 546/4885PGR 4381/4885
US-12479819-B2 Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities HCRTR2, HCRTR1, MCHR2 HTR2A 154/4885HRH1 106/4885PGR 1001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.